A labelling system improves parental comfort and willingness to use topical corticosteroids for paediatric atopic dermatitis.

ABSTRACT:

Objectives

In the United Kingdom, atopic dermatitis (AD) affects 20% of children and topical corticosteroids (TCS) are a mainstay of AD treatment regimes. Many TCS have similar packaging despite significant differences in potency frequently leading to confusion, and along with misinformation and steroid phobia, potentially reducing treatment adherence. We aimed to evaluate parents' knowledge/concerns regarding TCS and explore benefits of/preference for a TCS-labelling system.

Method

Hundred parents of children with AD attending paediatric dermatology and/or allergy appointments completed mixed-methodology Survey 1 (knowledge-quiz, TCS-labelling options, feedback on what supports AD-care). Thirty parents, adolescents, and healthcare professionals completed Survey 2. Qualitati

SUBMITTER: Wilson F 

PROVIDER: S-EPMC9060095 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature